Merck & Co., Inc. — 13F Holdings & Portfolio

CIK 310158 · latest 13F-HR filed 2026-08-07

Merck & Co., Inc. manages $526.4M in 13F-reported U.S. long-equity assets across 13 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are PSNL (35.75%), MRNA (30.71%), KYMR (16.82%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 3 new positions and exited 4; 8 existing positions rose in reported value and 2 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$526.4M

Long-equity book

Holdings
13

Distinct positions

Period
2026-06-30

Filed 2026-08-07

Q/Q Activity
+3 / −4 / ↑8 / ↓2

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 99.8%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People
Name Title / Status Ownership Type

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Top Adds (vs prior quarter)

Show all 8 →

Top Trims

Show all 2 →

Exited Positions

Show all 4 →

Merck & Co., Inc. Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 PERSONALIS INC PSNL 71535D106 $188.2M 35.75% 14,044,943 SH
2 MODERNA INC MRNA 60770K107 $161.6M 30.71% 2,308,190 SH
3 KYMERA THERAPEUTICS INC KYMR 501575104 $88.5M 16.82% 772,165 SH
4 AKTIS ONCOLOGY INC AKTS 01021M104 $30.7M 5.83% 952,844 SH
5 EIKON THERAPEUTICS INC EIKN 282564103 $21.7M 4.13% 1,666,666 SH
6 ENTRADA THERAPEUTICS INC TRDA 29384C108 $12.8M 2.43% 1,739,768 SH
7 SUTRO BIOPHARMA INC STRO 869367201 $9.0M 1.72% 272,351 SH
8 ALECTOR INC ALEC 014442107 $7.1M 1.35% 3,545,719 SH
9 EVAXION BIOTECH A/S EVAX 29970R303 $3.8M 0.71% 1,214,126 SH
10 VIRIDIAN THERAPEUTICS INC VRDN 92790C104 $1.7M 0.33% 93,414 SH
11 XILIO THERAPEUTICS INC XLO 98422T209 $1.0M 0.19% 105,982 SH
12 TUHURA BIOSCIENCES INC HURA 898920103 $45.5K 0.01% 19,445 SH
13 NEUPHORIA THERAPEUTICS INC NEUP 64136E102 $43.8K 0.01% 10,027 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-07 $526.4M 13 0000310158-26-000210
2026-03-31 2026-05-13 $349.4M 14 0000310158-26-000141
2025-12-31 2026-02-17 $276.3M 12 0000310158-26-000055
2025-09-30 2025-11-12 $228.0M 13 0000310158-25-000063
Filer Information
Address
126 EAST LINCOLN AVENUE
P.O. BOX 2000
RAHWAY, NJ 07065
Phone
(908) 740-4000
Filing Manager
Merck & Co., Inc.
RAHWAY, NJ
Signatory
Kelly Grez
Corporate Secretary